Boudry, Switzerland (Press Release) - Celgene Inter­na­tional Sàrl, a wholly-owned sub­sid­i­ary of Celgene Corpo­ra­tion (NASDAQ: CELG) today announced that the European Com­mis­sion (EC) has granted approval for Poma­lido­mide Celgene^® (poma­lido­mide), in com­bi­na­tion with dexa­meth­a­sone, for the treat­ment of re­lapsed and refractory multiple myeloma (rrMM) in adult patients who have received at least two prior ther­a­pies in­­clud­ing both lena­lido­mide and bor­tez­o­mib and have dem­onstrated disease pro­gres­sion on the last ther­apy.¹ Celgene intends to launch Poma­lido­mide Celgene in the EU under the trade name “IMNOVID^®”, fol­low­ing sub­mission of a regu­la­tory notification to the European Medicines …

Decision could sig­nif­i­cantly im­prove trans­plant out­comes for patients with multiple myeloma

Beerse, Belgium (Press Release) - Janssen-Cilag Inter­na­tional NV (Janssen) announced today that the European Com­mis­sion (EC) has approved the use of VELCADE^® (bor­tez­o­mib) as induction ther­apy (a first thera­peutic option) in com­bi­na­tion with dexa­meth­a­sone (VD) or thalido­mide and dexa­meth­a­sone (VTD).[1] This licence extension will apply to adult patients with pre­vi­ously-untreated multiple myeloma who are eligi­ble for high-dose chemo­ther­apy with haematological stem cell trans­plan­ta­tion.

Until now, VELCADE’s (bor­tez­o­mib) indi­ca­tion has been limited to its use, in com­bi­na­tion with mel­phalan and pred­ni­sone, in adult patients with multiple myeloma that are pre­vi­ously untreated and in­eli­gible for stem …

Boudry, Switzerland (Press Release) - Celgene Inter­na­tional Sàrl, a wholly-owned sub­sid­i­ary of Celgene Corpo­ra­tion (NASDAQ: CELG), today announced that data eval­u­ating treat­ment with REVLIMID^® (lena­lido­mide) in com­bi­na­tion with dexa­meth­a­sone followed by REVLIMID main­te­nance ther­apy in patients with high-risk asymptomatic smol­der­ing multiple myeloma were published in the August 1 edition of The New Eng­land Journal of Medicine. Smoldering multiple myeloma is an early, asymptomatic form of the disease char­ac­ter­ized by a 10% per year risk of pro­gres­sion to symp­tomatic disease over the first five years.

The Phase III, ran­dom­ized, multi­center, open-label study, led by Maria-Victoria Mateos, …

Boulder, CO (Press Release) - Array BioPharma Inc. (NASDAQ: ARRY) announced a strategic col­lab­o­ration with Celgene Corpo­ra­tion for an Array-invented pre­clin­i­cal devel­op­ment pro­gram targeting a novel inflam­ma­tion path­way.  Under the terms of the agree­ment Array will receive an up-front payment of $11 million and Celgene will have an exclusive option to license multiple clin­i­cal devel­op­ment can­di­dates. Array is entitled to receive poten­tial mile­stone payments of up to $376 million based upon achieving certain devel­op­ment, regu­la­tory and sales objectives. Array is also entitled to receive royalties on net sales of all drugs and will retain all rights …

Strategic Collaboration Includes Option for Celgene to Acquire Acetylon

Boston, MA (Press Release) - Acetylon Pharma­ceu­ticals, Inc., the leader in devel­op­ment of selective histone deacetylase (HDAC) inhibitors for en­hanced thera­peutic out­comes (the “Company”), today announced a strategic col­lab­o­ration and option agree­ment with Celgene Corpo­ra­tion (NASDAQ: CELG), which sup­ports the devel­op­ment of Acetylon’s portfolio of oral, selective HDAC inhibitors in on­col­ogy, hematology, im­mu­nol­ogy, and neurologic disease indi­ca­tions. The agree­ment in­cludes an exclusive option for the future acqui­si­tion of Acetylon by Celgene.

The col­lab­o­ration will focus on the con­tinued clin­i­cal ad­vancement of Acetylon’s lead …

The update will result in im­proved patient prognoses, better informed patient care de­ci­sions and reduced costs.

New York, NY and Little Rock, AR (Press Release) - Signal Genetics today announced that it has launched an update to its MyPRS gene ex­pres­sion assay for patients with Multiple Myeloma, which will im­prove patient prognoses, enable better informed patient care de­ci­sions, and ultimately reduce costs.

Every MyPRS test per­formed now in­cludes an analysis of an addi­tional set of 813-genes within the patient’s genome, which is used to create an individualized ‘Virtual Karyotype’ view of the …

Summit, NJ  (Press Release) - Celgene Corpo­ra­tion (NASDAQ: CELG) today announced that after consulta­tion with the U.S. Food and Drug Admin­istra­tion (FDA) Celgene will dis­con­tinue treat­ment with REVLIMID^® (lena­­lido­mide) in the open-label, phase III ORIGIN® trial, which enrolled 450 patients in over 100 sites in 26 countries. An imbalance was observed in the number of deaths in patients treated with lenalido­mide versus patients treated with chlorambucil.

The FDA placed the ORIGIN study on clin­i­cal hold on July 12, 2013, with the dis­con­tinu­a­tion of lena­lido­mide treat­ment. All clin­i­cal investigators in ongoing chronic lym­pho­cytic leukemia studies using lena­lido­mide will be officially …